Gossamer Bio, Inc.

GOSS
Kuhne v. Gossamer Bio, Inc., No. 3:20-cv-00649 (S.D. Cal.)

The lawsuit alleges violations of both the Securities Act and Securities Exchange Act regarding Gossamer's February 8, 2019 initial public offering. Specifically, Defendants are alleged to have misrepresented the cause of the failure of its phase 2 trial to investors. Defendants are also alleged to have misstated the success of a similar trial by Novartis.

On April 19, 2021, the Southern District of California issued a decision denying, in part, Defendants' Motions to Dismiss.